Clinical trials: Pulmonary Resistance
Multi-drug Resistant Tuberculosis
Case Control Study of Vitamin D Status and Adult Multidrug-resistant Pulmonary Tuberculosis in Maharashtra, India
India has the highest incidence of and mortality from multi-drug resistant tuberculosis (MDR-TB) globally. Vitamin D status may be an important determinant of MDR-TB infection and treatment outcomes; however, observational…
- Trial name
- NCT04342598
- Testing
- Serum Vitamin D
- Where
- India
- Volunteers
- 352 people, healthy volunteers welcome
- Sponsor
- Harvard School of Public Health (HSPH)
Pneumonia, Next-generation Sequencing
Monitoring of Antimicrobial Resistance Based on Metagenomics Analyses in Pneumonia Patients
Monitoring of antimicrobial resistance (AMR) based on metagenomics analyses in pneumonia patients is critical for optimizing clinical diagnosis and treatment and improving clinical prognosis.
- Conditions
- Pneumonia, Next-generation Sequencing, Microbiome, Antimicrobial Resistance
- Trial name
- NCT06566898
- Where
- China
- Volunteers
- 800 people
- Sponsor
- Shanghai General Hospital, China
Pneumonia
Clinical Outcomes of Methicillin Resistant Staphylococcus Aureus (MRSA) Hospital-Based Pneumonia
The purpose of this non-interventional, retrospective study of existing data is to evaluate clinical outcomes related to Methicillin-resistant Staphylococcus aureus hospital based pneumonia by treatment and among subpopulations.
- Trial name
- NCT01819935
- Testing
- linezolid (Zyvox), vancomycin
- Volunteers
- 5,271 people
- Sponsor
- Pfizer
Ovarian Neoplasms, Pancreatic Neoplasms
A Safety, Efficacy and Pharmacokinetic Study of Siltuximab (CNTO 328) in Participants With Solid Tumors
The purpose of this study is to determine the recommended dose of siltuximab monotherapy, in participants with solid malignant (cancerous) tumors (a mass in a specific area) and to estimate the clinical benefit of siltuximab…
- Conditions
- Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms, Head and Neck Neoplasms
- Trial name
- NCT00841191
- Testing
- CNTO 328; Anti-interleukin-6 monoclonal antibody
- Where
- 12 sites in United States, Belgium and 3 more
- Volunteers
- 84 people
- Sponsor
- Centocor, Inc.
Non-Small Cell Lung Cancer, Advanced Non-Small Cell Squamous Lung Cancer
Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations
BDTX-1535-101 is an open-label, Phase 1 dose escalation and Phase 2 multiple cohort study designed to evaluate the safety, pharmacokinetics (PK), optimal dosage, central nervous system (CNS) activity, and antitumor activity of…
- Conditions
- Non-Small Cell Lung Cancer, Advanced Non-Small Cell Squamous Lung Cancer, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Lung Cancer
- Trial name
- NCT05256290
- Testing
- silevertinib (BDTX-1535) monotherapy
- Where
- 25 sites in United States
- Volunteers
- 200 people
- Sponsor
- Black Diamond Therapeutics, Inc.
Lung Cancer
Analysis of Re-biopsy Specimens in Advanced NSCLC With Acquired Resistance of EGFR-TKI Targeted Therapy
The objective of the study is to reveal the acquired resistance mechanism of the first and second generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor (EGFR-TKI) in tissue and plasma using Next Generation…
- Trial name
- NCT03309462
- Testing
- Miseq sequencer
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Shanghai Chest Hospital
Covid19, SARS-CoV Infection
COVID-19 in Polish Ice Swimmers.
Ice swimming is an increasingly common phenomenon in Poland. It has been confirmed that it has a beneficial effect on health by increasing the natural non-specific immunity to infections.
- Conditions
- Covid19, SARS-CoV Infection, Resistance, Disease, Hypothermia
- Trial name
- ICE (NCT04817280)
- Testing
- Ice Swimming
- Where
- 3 sites in Poland
- Volunteers
- 2,534 people, healthy volunteers welcome
- Sponsor
- Wroclaw Medical University
Tuberculosis, HIV Infections
Evaluating the Safety, Tolerability, and Pharmacokinetics of Bedaquiline and Delamanid, Alone and in Combination, For Drug-Resistant Pulmonary Tuberculosis
This study evaluated the safety, tolerability, and pharmacokinetics of the anti-tuberculosis (TB) drugs bedaquiline (BDQ) and delamanid (DLM), alone and in combination, among participants (with or without HIV co-infection) taking…
- Trial name
- NCT02583048
- Testing
- Bedaquiline, Delamanid, Dolutegravir
- Where
- 3 sites in Peru, South Africa
- Volunteers
- 84 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Non Small Cell Lung Cancer
Tyrosine Kinase Inhibitors In Metastatic Non Small Cell Lung Cancer
Aim of the present retrospective study is to evaluate molecular factors of primary resistance to tyrosine kinase inhibitors in metastatic non small cell lung cancer (NSCLC) patients.
- Trial name
- NCT01163058
- Where
- Italy
- Volunteers
- 300 people
- Sponsor
- Istituto Clinico Humanitas
Cystic Fibrosis
STaph Aureus Resistance-Treat Early and Repeat (STAR-TER)
To evaluate the micro-biologic efficacy and safety of a streamlined treatment for early onset methicillin-resistant staphylococcus aureus (MRSA) in patients with cystic fibrosis.
- Trial name
- STAR-TER (NCT03489629)
- Testing
- Trimethoprim Sulfamethoxazole (TMP/SMX), Minocycline, Mupirocin
- Where
- 9 sites in United States
- Volunteers
- 49 people
- Sponsor
- University of North Carolina, Chapel Hill
Solid Tumors, Non-small Cell Lung Carcinoma
A Study of DS-2248 in Participants With Advanced Solid Tumors
This phase 1 clinical trial is intended to understand the safety and tolerability of a new anticancer drug in subjects with advanced solid tumors.
- Trial name
- NCT01288430
- Testing
- DS-2248
- Where
- 9 sites in United States
- Volunteers
- 60 people
- Sponsor
- Daiichi Sankyo
Pulmonary Hypertension, Mirabegron
Beta3 Agonist Treatment in Chronic Pulmonary Hypertension Secondary to Heart Failure
The purpose of this study is to evaluate the efficacy and safety of mirabegron (a B3 adrenergic receptor agonist) in patients with pulmonary hypertension secondary to heart failure by conducting a randomized multicenter phase II…
- Conditions
- Pulmonary Hypertension, Mirabegron, Heart Failure, Pulmonary Vascular Resistance Abnormality
- Trial name
- SPHERE-HF (NCT02775539)
- Testing
- Mirabegron
- Volunteers
- 80 people
- Sponsor
- Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III
Corticosteroid Resistant (CR) Asthmatics
Effects of p38 Inhibitor AZD7624 in Corticosteroid Resistant Asthma
This is a double-blind, placebo controlled 4 week crossover study to investigate the efficacy and safety of AZD7624 (an inhaled p38 inhibitor) in corticosteroid resistant (CR) asthmatics.
- Trial name
- NCT02753764
- Testing
- AZD7624, prednisone
- Where
- United States
- Volunteers
- 2 people, healthy volunteers welcome
- Sponsor
- National Jewish Health
Heart Failure, Respiratory Failure
Heart And Lung Failure - Pediatric INsulin Titration Trial
Stress hyperglycemia, a state of abnormal metabolism with supra-normal blood glucose levels, is often seen in critically ill patients.
- Trial name
- HALF-PINT (NCT01565941)
- Testing
- Insulin
- Where
- 35 sites in United States, Australia and 1 more
- Volunteers
- 713 people
- Sponsor
- Boston Children's Hospital
NSCLC
A Phase 2 Study of Osimertinib and S-1 in Treatment Resistant EGFR Mutant NSCLC
The objective of this study is to determine best overall response rate (BOR) based on radiological assessment per RECIST v1.1 to combination of S-1 and Osimertinib in treatment-resistant EGFR mutant lung cancer.
- Trial name
- NCT05773092
- Testing
- Oral S-1 + Oral Osimertinib
- Where
- Singapore
- Volunteers
- 30 people
- Sponsor
- National Cancer Centre, Singapore
Adenocarcinoma of Lung, Lung Neoplasm
An Integrated Approach to Treating Recurrent Thoracic Carcinomas Resistant to Tyrosine Kinase Inhibitors
Patients are asked to participate in this study if they have been diagnosed with a thoracic carcinoma which includes lung cancer and have a gene mutation (alteration in the body's genetic instructions) and after undergoing…
- Conditions
- Adenocarcinoma of Lung, Lung Neoplasm, Cancer of Lung, Lung Cancer
- Trial name
- NCT02616211
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Mayo Clinic
NSCLC, Non Small Cell Lung Cancer, RCC, Renal Cell Cancer
A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma
The purpose of this phase 2 study is to evaluate the efficacy and safety of NIR178 in combination with PDR001 in multiple solid tumors and diffuse large B-cell lymphoma (DLBCL) and further explore schedule variations of NIR178 to…
- Conditions
- NSCLC, Non Small Cell Lung Cancer, RCC, Renal Cell Cancer, Pancreatic Cancer, Urothelial Cancer
- Trial name
- NCT03207867
- Testing
- NIR178, PDR001
- Where
- 21 sites in United States, Argentina and 13 more
- Volunteers
- 315 people
- Sponsor
- Novartis Pharmaceuticals
NSCLC Stage IV, ALK Fusion Protein Expression
Peptide Vaccine To Prevent Acquired Resistance In Patients With Advanced ALK+ NSCLC
The purpose of this study is to evaluate the safety of a cancer peptide vaccine to prevent or delay acquired resistance in advanced ALK+ lung cancer patients currently on ALK targeted therapy.
- Trial name
- ARCHER (NCT05950139)
- Testing
- Peptide vaccine
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
High Grade Epithelial Ovarian Cancer, High Grade Serous Ovarian Cancer
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
This study will test the safety, including side effects, and determine the characteristics of a drug called Rina-S in participants with solid tumors.
- Conditions
- High Grade Epithelial Ovarian Cancer, High Grade Serous Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer
- Trial name
- RAINFOL-01 (NCT05579366)
- Testing
- Rina-S, Carboplatin, Bevacizumab
- Where
- 66 sites in United States, China and 1 more
- Volunteers
- 952 people
- Sponsor
- Genmab
Multi-drug Resistant Tuberculosis, Extensively Drug-Resistant Tuberculosis
Economic Evaluation of New MDR TB Regimens
The current treatment regimen for MDR-TB has poor outcomes and costs of treating MDR-TB are greater than treating drug susceptible TB, both in terms of health service and patient-incurred costs.
- Conditions
- Multi-drug Resistant Tuberculosis, Extensively Drug-Resistant Tuberculosis, Pulmonary Tuberculoses
- Trial name
- PRACTECAL-EE (NCT04207112)
- Testing
- Bedaquiline, Pretomanid, Moxifloxacin
- Where
- 7 sites in Belarus, South Africa and 1 more
- Volunteers
- 73 people
- Sponsor
- Medecins Sans Frontieres, Netherlands